HIMS Stock Price Today (July 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-07-17
Hims & Hers Health, Inc. (HIMS) is trading at $32.84, down 2.49% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $27.32 (-16.8% upside).
- Volatility remains elevated (61.48% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (3.80% YoY) alongside significant competitive pressures.
HIMS Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $8.41B
P/E Ratio
Forward P/E: 38.96
Revenue Growth
Year over Year
Analyst Target
+-16.8% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 44.31)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.13B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $70.43—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 61.48% annualized volatility and β=2.41, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
3 Reasons HIMS Has Explosive Upside Potential
Hims & Hers Health trades at $33.39 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time, the S&P 500 has returned 11.4%.
This Trade Offers Two Ways To Profit From Hims & Hers Stock
A cash-secured put on Hims & Hers stock is one way to potentially buy the stock for a discount or achieve a healthy return.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meeting
An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.
Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide Questions
Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples while only scoring weakly on broader valuation checks. A roughly 344.6% return over 3 years puts Hims & Hers Health among the stronger performers in digital health, which raises the bar for what future growth and execution need to justify. Recent traction in branded GLP-1 and peptide related offerings can support optimistic revenue expectations, but evolving FDA...
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $32.84. The RSI (14-day) is at 44.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $27.32 implies 16.8% downside from current levels. Volatility is high at 61.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is -364.89, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 38.96. The PEG ratio is 2.15, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 16.98. Price-to-Sales is 3.09. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering HIMS, the consensus price target is $27.32. This represents a 16.8% downside from the current price of $32.84. The range spans from a low target of $21.00 to a high target of $39.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (61.5% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 253.72) which could pressure margins in a rising rate environment. 3. Elevated short interest (34.1% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.13B. The debt-to-equity ratio is 253.72, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.69, indicating strong short-term liquidity. The quick ratio is 1.46. The company holds $750.88M in cash and equivalents. Free cash flow is positive at $174.31M, providing a cushion for debt servicing and shareholder returns.